Sana Biotechnology Inc
$ 2.82
0.00%
10 Jun - close price
- Market Cap 784,782,000 USD
- Current Price $ 2.82
- High / Low $ 2.91 / 2.76
- Stock P/E N/A
- Book Value 0.60
- EPS -0.92
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -1.47 %
- 52 Week High 6.55
- 52 Week Low 2.41
About
Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
Analyst Target Price
$8.57
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-03 | 2025-11-06 | 2025-08-11 | 2025-05-08 | 2025-03-17 | 2024-11-08 | 2024-08-08 | 2024-05-08 | 2024-02-29 | 2023-11-08 | 2023-08-03 |
| Reported EPS | -0.1705 | -0.16 | -0.16 | -0.39 | -0.2 | -0.23 | -0.25 | -0.32 | -0.32 | -0.41 | 0.02 | -0.59 |
| Estimated EPS | -0.13 | -0.1444 | -0.18 | -0.2 | -0.2 | -0.2428 | -0.27 | -0.28 | -0.32 | -0.38 | -0.45 | -0.43 |
| Surprise | -0.0405 | -0.0156 | 0.02 | -0.19 | 0 | 0.0128 | 0.02 | -0.04 | 0 | -0.03 | 0.47 | -0.16 |
| Surprise Percentage | -31.1538% | -10.8033% | 11.1111% | -95% | 0% | 5.2718% | 7.4074% | -14.2857% | 0% | -7.8947% | 104.4444% | -37.2093% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SANA
2026-06-12 04:09:58
Sana Biotechnology, Inc.'s average 12-month price target has been lowered from $9.50 to $9.14 by 7 analysts, with individual forecasts ranging from $7 to $16 per share. This updated target suggests a potential upside of approximately 230% from its Jun. 11 closing price. Despite the price target cut, the consensus rating from 9 analysts remains a "Buy," with 8 expressing a Buy and 1 a Hold.
2026-06-11 14:09:58
Sana Biotechnology has raised $69 million through an "at-the-market" (ATM) share offering. The company sold 8.6 million shares at an average price of $8.07 per share. This capital raise was executed through an amendment to a prior sales agreement with Cowen and Company and SVB Securities.
2026-06-06 10:40:08
This page provides a comprehensive resource for Sana Biotechnology, Inc. (SANA) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. Recent disclosures cover executive changes, financial results with asset write-downs, capital raises, and positive clinical trial updates for UP421. The platform tracks 49 filings, offering AI-generated summaries, impact scoring, and sentiment analysis for investors.
2026-06-06 08:09:20
This article is a statement of changes in beneficial ownership of securities for Sana Biotechnology, specifically concerning Director Joshua H. Bilenker. This indicates a transaction related to his holdings in the company.
2026-06-06 07:10:07
Sana Biotechnology director Alise Reicin was granted 90,000 stock options with an exercise price of $2.96 per share, expiring on June 3, 2036. These options vest 100% on the earlier of June 4, 2027, or immediately before the 2027 annual stockholder meeting, provided continuous service. This grant is considered a routine equity compensation event aimed at retention rather than a market trading signal.
2026-06-06 07:10:07
Sana Biotechnology director Robert L. Rosiello was granted 90,000 stock options with an exercise price of $2.96 per share, expiring on June 3, 2036. The options will fully vest on the earlier of June 4, 2027, or just before Sana's 2027 annual shareholder meeting, provided Rosiello maintains continuous service. This is a compensation award, not an open-market purchase, and is detailed in a Form 4 SEC filing.
